NCT02600975View on ClinicalTrials.gov

A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01B

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 8, 2015

Primary Completion Date

January 19, 2017

Study Completion Date

January 19, 2017

Conditions
Malaria
Interventions
BIOLOGICAL

R21 with ASO1B

R21 with ASO1B

Trial Locations (2)

OX3 7LE

CCVTM, University of Oxford, Oxford

SO16 6YD

NIHR Wellcome Trust Clinical Research Facility, Southampton

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02600975 - A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01B | Biotech Hunter | Biotech Hunter